
Adam C. Milligan
Examiner (ID: 858, Phone: (571)270-7674 , Office: P/1612 )
| Most Active Art Unit | 1612 |
| Art Unit(s) | 1623, 1612 |
| Total Applications | 585 |
| Issued Applications | 143 |
| Pending Applications | 10 |
| Abandoned Applications | 437 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19125663
[patent_doc_number] => 20240131016
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => IRAK DEGRADERS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/360277
[patent_app_country] => US
[patent_app_date] => 2023-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18360277
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/360277 | IRAK DEGRADERS AND USES THEREOF | Jul 26, 2023 | Pending |
Array
(
[id] => 19125663
[patent_doc_number] => 20240131016
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => IRAK DEGRADERS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/360277
[patent_app_country] => US
[patent_app_date] => 2023-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18360277
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/360277 | IRAK DEGRADERS AND USES THEREOF | Jul 26, 2023 | Pending |
Array
(
[id] => 18947107
[patent_doc_number] => 11890380
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-02-06
[patent_title] => Buccal formulation of avanafil with enhanced bioavailability and prolonged duration
[patent_app_type] => utility
[patent_app_number] => 18/191259
[patent_app_country] => US
[patent_app_date] => 2023-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 10759
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 161
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18191259
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/191259 | Buccal formulation of avanafil with enhanced bioavailability and prolonged duration | Mar 27, 2023 | Issued |
Array
(
[id] => 18323080
[patent_doc_number] => 20230121208
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => Dispersible Tablet For Oral Administration
[patent_app_type] => utility
[patent_app_number] => 18/081875
[patent_app_country] => US
[patent_app_date] => 2022-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9589
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18081875
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/081875 | Dispersible Tablet For Oral Administration | Dec 14, 2022 | Abandoned |
Array
(
[id] => 18254464
[patent_doc_number] => 20230081503
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION
[patent_app_type] => utility
[patent_app_number] => 17/990312
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19715
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990312
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990312 | Use of sublingual dexmedetomidine for the treatment of agitation | Nov 17, 2022 | Issued |
Array
(
[id] => 18368058
[patent_doc_number] => 11648205
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-05-16
[patent_title] => Buccal formulation of avanafil with enhanced bioavailability and prolonged duration
[patent_app_type] => utility
[patent_app_number] => 18/046700
[patent_app_country] => US
[patent_app_date] => 2022-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 8
[patent_no_of_words] => 10842
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046700
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/046700 | Buccal formulation of avanafil with enhanced bioavailability and prolonged duration | Oct 13, 2022 | Issued |
Array
(
[id] => 18142969
[patent_doc_number] => 20230016814
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => MARKERS FOR PHARMACEUTICALS
[patent_app_type] => utility
[patent_app_number] => 17/947780
[patent_app_country] => US
[patent_app_date] => 2022-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6818
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17947780
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/947780 | MARKERS FOR PHARMACEUTICALS | Sep 18, 2022 | Abandoned |
Array
(
[id] => 17913118
[patent_doc_number] => 20220315513
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => 11-HALO-1,1-DIALKOXY-7-UNDECENE COMPOUND AND PROCESSES FOR PREPARING A 11,11-DIALKOXY-4-UNDECENYLTRIARYLPHOSPHONIUM HALIDE COMPOUND, A TRIENAL COMPOUND, AND A DIENAL COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/698022
[patent_app_country] => US
[patent_app_date] => 2022-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16139
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17698022
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/698022 | 11-halo-1,1-dialkoxy-7-undecene compound and processes for preparing a 11,11-dialkoxy-4-undecenyltriarylphosphonium halide compound, a trienal compound, and a dienal compound | Mar 17, 2022 | Issued |
Array
(
[id] => 17913118
[patent_doc_number] => 20220315513
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => 11-HALO-1,1-DIALKOXY-7-UNDECENE COMPOUND AND PROCESSES FOR PREPARING A 11,11-DIALKOXY-4-UNDECENYLTRIARYLPHOSPHONIUM HALIDE COMPOUND, A TRIENAL COMPOUND, AND A DIENAL COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/698022
[patent_app_country] => US
[patent_app_date] => 2022-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16139
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17698022
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/698022 | 11-halo-1,1-dialkoxy-7-undecene compound and processes for preparing a 11,11-dialkoxy-4-undecenyltriarylphosphonium halide compound, a trienal compound, and a dienal compound | Mar 17, 2022 | Issued |
Array
(
[id] => 17546665
[patent_doc_number] => 20220118006
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => MAGNESIUM/LITHIUM PREPARATIONS FOR NEUROPROTECTION AND NEUROTROPHIC BENEFITS
[patent_app_type] => utility
[patent_app_number] => 17/567643
[patent_app_country] => US
[patent_app_date] => 2022-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4035
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17567643
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/567643 | MAGNESIUM/LITHIUM PREPARATIONS FOR NEUROPROTECTION AND NEUROTROPHIC BENEFITS | Jan 2, 2022 | Abandoned |
Array
(
[id] => 18324224
[patent_doc_number] => 20230122352
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => METHOD OF TREATING ORAL PAIN WITH AN EFFERVESCING COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/451241
[patent_app_country] => US
[patent_app_date] => 2021-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 794
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17451241
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/451241 | METHOD OF TREATING ORAL PAIN WITH AN EFFERVESCING COMPOSITION | Oct 17, 2021 | Abandoned |
Array
(
[id] => 17383757
[patent_doc_number] => 20220031609
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => ORGANIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/501173
[patent_app_country] => US
[patent_app_date] => 2021-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5960
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17501173
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/501173 | ORGANIC COMPOUNDS | Oct 13, 2021 | Abandoned |
Array
(
[id] => 17881027
[patent_doc_number] => 20220296504
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => INTRANASAL DELIVERY OF LEVODOPA POWDER BY PRECISION OLFACTORY DEVICE
[patent_app_type] => utility
[patent_app_number] => 17/498381
[patent_app_country] => US
[patent_app_date] => 2021-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14240
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498381
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/498381 | INTRANASAL DELIVERY OF LEVODOPA POWDER BY PRECISION OLFACTORY DEVICE | Oct 10, 2021 | Abandoned |
Array
(
[id] => 17383811
[patent_doc_number] => 20220031663
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION
[patent_app_type] => utility
[patent_app_number] => 17/496470
[patent_app_country] => US
[patent_app_date] => 2021-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19797
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17496470
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/496470 | Use of sublingual dexmedetomidine for the treatment of agitation | Oct 6, 2021 | Issued |
Array
(
[id] => 17183705
[patent_doc_number] => 20210330590
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => AGENTS FOR ORAL COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/367714
[patent_app_country] => US
[patent_app_date] => 2021-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19980
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367714
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/367714 | AGENTS FOR ORAL COMPOSITION | Jul 5, 2021 | Pending |
Array
(
[id] => 17183705
[patent_doc_number] => 20210330590
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => AGENTS FOR ORAL COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/367714
[patent_app_country] => US
[patent_app_date] => 2021-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19980
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367714
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/367714 | AGENTS FOR ORAL COMPOSITION | Jul 5, 2021 | Pending |
Array
(
[id] => 18496054
[patent_doc_number] => 20230218589
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => COMPOUND FOR PREVENTION OR TREATMENT OF A SKIN CANCER OR SKIN PRECANCER
[patent_app_type] => utility
[patent_app_number] => 18/009642
[patent_app_country] => US
[patent_app_date] => 2021-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16151
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009642
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/009642 | COMPOUND FOR PREVENTION OR TREATMENT OF A SKIN CANCER OR SKIN PRECANCER | Jun 8, 2021 | Pending |
Array
(
[id] => 17124321
[patent_doc_number] => 20210299089
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/332800
[patent_app_country] => US
[patent_app_date] => 2021-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25359
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332800
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/332800 | Administration of benzodiazepine compositions | May 26, 2021 | Issued |
Array
(
[id] => 17005301
[patent_doc_number] => 20210236462
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => SUSTAINED RELEASE LINGUAL THIOCTIC ACID DELIVERY SYSTEMS
[patent_app_type] => utility
[patent_app_number] => 17/236972
[patent_app_country] => US
[patent_app_date] => 2021-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16461
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17236972
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/236972 | SUSTAINED RELEASE LINGUAL THIOCTIC ACID DELIVERY SYSTEMS | Apr 20, 2021 | Abandoned |
Array
(
[id] => 18716465
[patent_doc_number] => 11793786
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-24
[patent_title] => Administration of benzodiazepine compositions
[patent_app_type] => utility
[patent_app_number] => 17/228514
[patent_app_country] => US
[patent_app_date] => 2021-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25350
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17228514
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/228514 | Administration of benzodiazepine compositions | Apr 11, 2021 | Issued |